EA201990513A1 - АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ - Google Patents

АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ

Info

Publication number
EA201990513A1
EA201990513A1 EA201990513A EA201990513A EA201990513A1 EA 201990513 A1 EA201990513 A1 EA 201990513A1 EA 201990513 A EA201990513 A EA 201990513A EA 201990513 A EA201990513 A EA 201990513A EA 201990513 A1 EA201990513 A1 EA 201990513A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
bone diseases
pparγ agonist
pparγ
agonist
Prior art date
Application number
EA201990513A
Other languages
English (en)
Inventor
Деннис Ланфир
Original Assignee
Интекрин Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интекрин Терапьютикс, Инк. filed Critical Интекрин Терапьютикс, Инк.
Publication of EA201990513A1 publication Critical patent/EA201990513A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Способы лечения поражения костей, включая остеопороз или его симптомы, с использованием агонистов PPARγ и, в частности, соединения формулы (I), известного как INT131
EA201990513A 2016-08-18 2017-08-18 АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ EA201990513A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376732P 2016-08-18 2016-08-18
PCT/US2017/047584 WO2018035449A1 (en) 2016-08-18 2017-08-18 Pparϒ agonist for treatment of bone disorders

Publications (1)

Publication Number Publication Date
EA201990513A1 true EA201990513A1 (ru) 2019-08-30

Family

ID=61197122

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990513A EA201990513A1 (ru) 2016-08-18 2017-08-18 АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ

Country Status (11)

Country Link
US (1) US20190167660A1 (ru)
EP (1) EP3500269A4 (ru)
JP (2) JP2019524889A (ru)
KR (1) KR20190065252A (ru)
CN (1) CN109843292A (ru)
AU (1) AU2017313842A1 (ru)
BR (1) BR112019003133A2 (ru)
CA (1) CA3033971A1 (ru)
EA (1) EA201990513A1 (ru)
SG (2) SG11201901328VA (ru)
WO (1) WO2018035449A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507914A (ja) 2015-03-09 2018-03-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152451A0 (en) * 2000-04-28 2003-05-29 Sankyo Co 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
CA2899187C (en) * 2013-01-30 2016-06-07 Intekrin Therapeutics, Inc. Ppary agonists for treatment of multiple sclerosis
DK3203999T3 (da) * 2014-10-10 2020-03-30 Liminal Biosciences Ltd Substituerede aromatiske forbindelser og farmaceutiske sammensætninger til forebyggelse og behandling af osteoporose

Also Published As

Publication number Publication date
KR20190065252A (ko) 2019-06-11
JP2019524889A (ja) 2019-09-05
AU2017313842A1 (en) 2019-03-07
CA3033971A1 (en) 2018-02-22
CN109843292A (zh) 2019-06-04
WO2018035449A1 (en) 2018-02-22
US20190167660A1 (en) 2019-06-06
EP3500269A1 (en) 2019-06-26
JP2022116294A (ja) 2022-08-09
EP3500269A4 (en) 2020-04-15
BR112019003133A2 (pt) 2019-05-21
SG10202101500WA (en) 2021-03-30
SG11201901328VA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
CU20210029A7 (es) Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
EA201691135A1 (ru) Новые ингибиторы глутаминазы
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
CR20200362A (es) CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
MY195437A (en) Methods of Treatment for Cholestatic and Fibrotic Diseases
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EA201790398A1 (ru) Способы лечения заболевания печени
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EA201692480A1 (ru) Фармацевтическая композиция
EA201791095A1 (ru) Способ лечения рака
BR112016015236A2 (pt) inibidores de serina/treonina quinase
EA201890567A1 (ru) Способ лечения рака
EA201791451A1 (ru) 5-[(пиперазин-1-ил)-3-оксо-пропил]-имидазолидин-2,4-дионовые производные в качестве ингибиторов adamts для лечения остеоартрита
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
EA201591399A1 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА